Narrative review· 2018

Thymosin beta 4 and the eye: the journey from bench to bedside

Sosne G

Expert opinion on biological therapy

DOI
10.1080/14712598.2018.1486818
PubMed
30063853
Evidence level
review
Verification
needs_review

Summary

Sosne 2018 (Expert Opin Biol Ther) first-person autobiographical review covering the development of thymosin β4 as an ocular-surface therapy from bench to Phase 3 clinical trials in dry-eye disease and neurotrophic keratopathy.

Limitations

Autobiographical/editorial format with strongly promotional tone in the abstract ("thrilling exhilaration", "electrifying possibility"); single-author review; the underlying evidence base is the referenced Phase 3 trials, not this paper itself; not suitable as a stand-alone evidence source.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.